Risk factors associated with patients with microscopic colitis
Keywords:
microscopic colitis, lymphocytic colitis, collagenous colitis, risk factorsAbstract
Introduction: the first description of microscopic colitis was made in 1976. Currently, it groups three subgroups of pathologies, the classic lymphocytic colitis and collagenous colitis, the third subgroup corresponds to incomplete microscopic colitis.
Objective: to identify the main factors associated with the development of microscopic colitis at the Hospital General Provincial "Carlos Manuel de Céspedes", Bayamo, Granma, from March 2019 to August 2021.
Method: an observational, analytical study of cases and controls was carried out in patients aged 18 years or older with chronic watery diarrhea treated at the gastroenterology service. The variables studied were: presence of microscopic colitis, age, sex, smoking habit, use of medications, comorbidities, abdominal pain, fatigue, fecal incontinence and weight loss. The sample size for paired studies was determined using the STATA 17 program. For its estimation, the following were considered: confidence level, statistical power of the test, ratio of cases and controls and minimum Odds Ratio.
Results: there was no association between age over 50 years and the probability of presenting colitis. The female sex prevailed (62.5%). Of the total number of patients with microscopic colitis (n=16), 62.5% smoked. The OR obtained indicated that smoker patients have 2.5 times more risk. Diabetes mellitus was significantly associated with the diagnosis of microscopic colitis and increased the risk fivefold.
Conclusions: there is a relationship between female sex, smoking, diabetes mellitus, cholecystectomy, consumption of three or more drugs and fecal incontinence with the presence of microscopic colitis.
Downloads
References
2. Prieto Ortiz RG, Prieto Ortiz JE. Colitis microscópica, un diagnóstico en aumento. Revisiones de tema. Rev Colomb Gastroenterol [Internet]. 2019 [citado 24 Mayo 2022] 34(4):339-403. DOI: https://doi.org/10.22516/25007440.377
3. Zabana Y, Ferrer C, Aceituno M, Salas A, Fernández-Bañares F. Colitis microscópica: avances para una mejor identificación en los pacientes con diarrea crónica. Gastroenterol Hepatol [Internet]. 2017 [citado 12 Dic 2021]; 40(2):107-116. DOI: https://doi.org/10.1016/j.gastrohep.2016.01.013
4. Miehlke S, Guagnozzi D, Zabana Y, Tontini GE, Kanstrup Fiehn AM, Wildt S, et al. European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. United Europ Gastroenterol J [Internet]. 2021 Feb. [citado 24 Mayo 2022]; 9(1):13-37. DOI: https://doi.org/10.1177/2050640620951905
5. Rojas BR. Diagnóstico y manejo de la colitis microscópica. Gastroenterol Latinoam [Internet]. 2019 [citado 22 Sept 2021]; 30(supl 1):s35-s38. Disponible en: https://gastrolat.org/diagnostico-y-manejo-de-la-colitis-microscopica/
6. Betancourt-Vicencio S, García-Monroy D, Garrido-Cepeda MEJ, Cabrera-Ordoñez C, Romero-Gómez F, Latorraca-Santamaría JI, et al. Colitis microscópica: serie de casos y revisión de la bibliografía. Rev Méd MD [Internet] 2019 May-Jul [citado 22 Sept 2021]; 10(4):265-270. Disponible en: https://www.medigraphic.com/pdfs/revmed/md-2019/md194f.pdf
7. Davidson S, Sjobeig K, Engel PLH, Lorinc E, Fiehn A-MK, Vigren L, et al. Microscopic colitis en Denmark and Sweden; incidence, putatne risk factor, histologred assessmeril and endoscopic activity. Scand J Gastroenterol [Internet]. 2018 [citado 22 Sept 2021]; 53(7):818-824. DOI: https://doi.org/10.1080/00365521.2018.1476583
8. Green HD, Beaumont RN, Thomas A, Hamilton B, Wood AR, Sharp S, et al. Genome-wide association stady of microscopic colitis in the UK biobank confirms immune related pathogenesis. J Crohns Colitis [Internet]. 2019 [citado 9 Jul 2022]; 13(12):1578-1582. DOI: https://doi.org/10.1093/ecco-jcc/jjz104
9. Lyutakov I, Lozanov V, Sugareva P, Valkov H, Penchev P. Serum 7 alfa-hydroxy-4 cholesten-3- one and fibroblast growth factor-19 as biomarkers diagnosing bile acid malabsorption in microscopic colitis and inflammatory bowel disease. Europ J Gastroenterol Hepatol [Internet]. 2021 [citado 19 Jul 2022]; 33(3):380-387. DOI: https://doi.org./10.1097/MEG.0000000000001925
10.Verhaegh BPM, Vries F de, Masclee AAM, Keshavarzian A, Boer A de, Souverein PC, et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther [Internet]. 2016 [citado 22 Jul 2022]; 43:1004-1013. DOI: https://doi.org/10.1111/apt.13583
11.Law EH, Badoiwski M, Hung Y, Weems K, Sánchez A, Lee TA. Association between proton pump inhibitor and microscopic colitis: Implications for practice and future research. Ann Pharmacother [Internet]. 2016 [citado 22 Jul 2022]. DOI: https://doi.org./10.1177/1060028016673859
12.Rashidian A, Muhammadnejad A, Dehpour AR, Ejtemai Mehr S, Akhavan Maziar M, et al. Atorvastatin attenuates TNBS-induced rat colitis: the involvement of the TLR4-KB signaling pathway. Inflammopharmacol [Internet]. 2016 [citado 23 Jul 2022]; 24:109-118. DOI: https://doi.org./10.1007/s101887-016-0263-6
13.Nielsen HL, Dalager-Pedersen M, Nielsen H. High risk of microscopic colitis after campylobacter concisus infection: population- based cohort study. Inflamm Bowel Dis [Internet]. 2020 Nov. [citado 24 Jul 2022]; 69(11):1952-1958. DOI: https://doi.org./10.1136/gutjnl-2019-319771
14.Kane JS, Irvine AJ, Derwa Y, Ford AC. Fatigue and its associated factors in microscopic colitis. Therap Adv Gastroenterol [Internet]. 2018 [citado 8 Sep 2022]; 11:1-10. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137548/
15.Lucendo AJ, Fernández-Bañares F. Colitis microscópica y exposición a fármacos: una revisión crítica. Enferm inflam intest dia [Internet]. 2015 [citado 25 Jul 2022]; 14(3):94-104. DOI: http://dx.doi.org/10.1016/J.eii.2015.08.004
